Detlev Biniszkiewicz
Executive Partner @ MPM Capital
Cambridge, United States
Detlev Biniszkiewicz is a Series B investor at MPM Capital in Cambridge focused on Health Care and Biotechnology. Detlev Biniszkiewicz, Ph.D., joined MPM in 2018 as a Managing Director and is responsible for the identification and evaluation of new investment opportunities as well as providing operational and strategic guidance to the firm’s portfolio investments. Detlev is an experienced biopharma executive and brings deep knowledge of oncology andimmuno-oncology to this role.Most recently, Detlev was the President and CEO of Surface Oncology (SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso® – two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical alliances, and academic collaborations. Detlev has also held multiple roles at Novartis including Global Head of Portfolio Management and Analysis, where his group provided oversight of Novartis’ research and early development portfolio.Detlev began his career as a Principal at the Boston Consulting Group (BCG) and performed his academic research with Dr. Rudolf Jaenisch at the Whitehead Institute at the Massachusetts Institute of Technology in Cambridge, MA.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Detlev Biniszkiewicz invests in
Stages Detlev Biniszkiewicz invests in
Countries Detlev Biniszkiewicz invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Life Science 1 (33%)
- Therapeutics 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NextPoint Therapeutics
|
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M / Series B / Feb 14, 2024 | |
Deka Biosciences
|
Early stage biotechnology start-up developing next generation cytokine therapeutics | $20M / Series B / Sep 28, 2023 | |
|
Deka Biosciences
|
Early stage biotechnology start-up developing next generation cytokine therapeutics | $20M / Series B / Sep 28, 2023 |
Co-Investors
About MPM Capital
MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.
MPM Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David P. Ryan
Medical and Scientific Advisor
|
|||
|
Detlev Biniszkiewicz
Executive Partner
|
|||
Uciane Scarlett
Principal
|
|||
Ansbert Gadicke
Managing Director and Co-Founder
|
|||
Bard Geesaman
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Detlev Biniszkiewicz invest in?
Detlev Biniszkiewicz invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Detlev Biniszkiewicz last invest?
The most recent investment recorded for Detlev Biniszkiewicz closed in Feb 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
